Most cancer drugs attack something on the tumour cell: a receptor, an enzyme, a signalling pathway or a surface protein. TTX-MC138 takes a different approach. It is designed to inhibit microRNA-10b (miR-10b), a small regulatory RNA strongly associated with invasion, metastatic progression and survival of metastatic tumour cells. The idea is unusually ambitious: rather than […]
PSMA has transformed prostate cancer imaging and radioligand therapy, but it is not the only useful target on prostate cancer cells. A new pivotal trial, SPARROW, is now testing 68Ga-DOTA-RM2, a PET tracer that targets the gastrin-releasing peptide receptor, or GRPR, in men with prostate cancer. The study is designed to determine how accurately GRPR-PET […]
For men with localised low- or intermediate-risk prostate cancer who need treatment, one of the biggest decisions is whether to choose surgery or radiotherapy. The phase 3 PACE-A trial is the first randomised study to directly compare modern prostatectomy with stereotactic body radiotherapy (SBRT) delivered in just five treatments. New long-term results presented at ASTRO […]
A new analysis of the phase 3 ARCHES trial suggests that a simple clinical model may help predict which men with metastatic hormone-sensitive prostate cancer are most likely to achieve a very deep PSA response after starting treatment with an androgen-receptor pathway inhibitor. The model, called NADIR, was designed to estimate the probability of reaching […]
Platinum chemotherapy is not usually considered a standard targeted treatment for metastatic prostate cancer, but the phase 2 CIPHER trial suggests that carboplatin may have meaningful activity in men with mCRPC carrying homologous recombination repair (HRR) mutations. The study enrolled 39 patients with HRR-altered mCRPC who had already received at least one androgen-receptor pathway inhibitor […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Another promising week for us! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. Clinical Research Phase 2 Trial: ENV105 Combined with Apalutamide in […]
Neuroendocrine prostate cancer is one of the most aggressive forms of the disease and remains particularly difficult to treat. A new Oncogene study has identified a possible mechanism that helps these tumours suppress the immune response, centred on a molecule called Neuromedin U, or NMU. In mouse models of neuroendocrine prostate cancer, the researchers found […]
CAR-T therapy has transformed some blood cancers, but solid tumors remain much more difficult. One major problem is tumor heterogeneity: not every cancer cell expresses the same target, and tumours can change over time. A new preclinical study published in Cancer Immunology Research describes a way to make CAR-T cells more adaptable. The researchers created […]
B7-H3 has become one of the most interesting targets in advanced prostate cancer, especially for antibody-drug conjugates and other targeted treatments. A new Cancer Discovery study suggests that B7-H3 may not simply sit on the surface of tumour cells: it may actively help the cancer suppress the immune system and resist treatment. The researchers found […]
A new phase 2 trial will test JNJ-101556143, also known as HLD-0915, in men with metastatic prostate cancer that has become resistant to androgen-pathway treatment. The study plans to enrol about 100 patients and will evaluate whether the drug can produce objective tumour responses, making this a clear step beyond the earlier dose-finding programme. JNJ-101556143 […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy